| Name | Title | Contact Details |
|---|
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
Gravie has been at the forefront of driving change and improving the healthcare industry by creating innovative employer-sponsored health benefit solutions that put consumers first. Comfort™, Gravie`s flagship product, is the nation`s first-of-its-kind health plan that provides zero-deductible, zero-copay, and 100% coverage on most common healthcare services, at a cost comparable to most traditional group health plans.
Trinity Communications is a Media, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Providence Health & Services is a non-profit, Catholic health care system operating multiple hospitals across eight states, with headquarters in Renton, Washington.
New York County Health Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.